View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		92,449,197
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 7,849,000	$ 15,506,000
Accounts receivable, net of reserves of $1,566,000 and of $1,445,000 in 2014 and 2013, respectively	532,000	4,152,000
Inventories, net	5,020,000	3,694,000
Other current assets	1,245,000	1,225,000
Total current assets	14,646,000	24,577,000
Property and equipment, net	1,571,000	1,054,000
Restricted cash and cash equivalents	350,000	350,000
Other assets	2,291,000	2,812,000
Intangibles, net	9,534,000	9,345,000
Goodwill	3,922,000	3,922,000
Total assets	32,314,000	42,060,000
Current liabilities:
Accounts payable and accrued expenses	5,739,000	6,077,000
Current portion of long-term obligations, net of discount	5,477,000	3,191,000
Termination fee obligation	0	400,000
Puregraft divestiture obligation	158,000	547,000
Joint Venture purchase obligation	2,817,000	4,691,000
Warrant liability	287,000	0
Total current liabilities	14,478,000	14,906,000
Deferred revenues	168,000	212,000
Long-term deferred rent and other	629,000	710,000
Long-term obligations, net of discount, less current portion	20,332,000	23,100,000
Total liabilities	35,607,000	38,928,000
Commitments and contingencies
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2014 and 2013	0	0
Common stock, $0.001 par value; 145,000,000 shares authorized; 83,574,164 and 71,305,375 shares issued and outstanding in 2014 and 2013, respectively	83,000	71,000
Additional paid-in capital	328,684,000	303,710,000
Accumulated other comprehensive income	457,000	256,000
Accumulated deficit	(332,517,000)	(300,905,000)
Total stockholders' (deficit) equity	(3,293,000)	3,132,000
Total liabilities and stockholders' (deficit) equity	$ 32,314,000	$ 42,060,000

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Accounts receivable, reserves	$ 1,566,000	$ 1,445,000
Stockholders' (deficit) equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	145,000,000	145,000,000
Common stock, shares issued (in shares)	83,574,164	71,305,375
Common stock, shares outstanding (in shares)	83,574,164	71,305,375

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) [Abstract]
Product revenues	$ 518,000	$ 1,616,000	$ 2,484,000	$ 4,416,000
Cost of product revenues	337,000	931,000	1,524,000	2,296,000
Gross profit	181,000	685,000	960,000	2,120,000
Development revenues:
Development, related party	0	0	0	638,000
Development revenue	0	0	0	1,179,000
Government contracts and other	585,000	1,095,000	1,345,000	2,503,000
Total development revenues	585,000	1,095,000	1,345,000	4,320,000
Operating expenses:
Research and development	3,140,000	4,123,000	12,106,000	11,992,000
Sales and marketing	1,471,000	1,786,000	5,332,000	6,453,000
General and administrative	4,179,000	4,332,000	13,121,000	12,225,000
Change in fair value of warrant liability	(134,000)	0	(134,000)	(418,000)
Change in fair value of option liability	0	0	0	(2,250,000)
Total operating expenses	8,656,000	10,241,000	30,425,000	28,002,000
Operating loss	(7,890,000)	(8,461,000)	(28,120,000)	(21,562,000)
Other income (expense):
Loss on asset disposal	(14,000)	0	(15,000)	(257,000)
Gain on Puregraft divestiture	0	4,392,000	0	4,392,000
Gain on previously held equity interest in joint venture	0	0	0	4,892,000
Loss on debt extinguishment	0	0	0	(708,000)
Interest income	1,000	1,000	4,000	2,000
Interest expense	(1,260,000)	(1,094,000)	(3,286,000)	(2,456,000)
Other income (expense), net	(222,000)	(96,000)	(195,000)	(392,000)
Equity loss from investment in joint venture	0	0	0	(48,000)
Total other income (expense)	(1,495,000)	3,203,000	(3,492,000)	5,425,000
Net loss	(9,385,000)	(5,258,000)	(31,612,000)	(16,137,000)
Other comprehensive income (loss) foreign currency translation adjustments	58,000	(108,000)	201,000	(142,000)
Net comprehensive loss	$ (9,327,000)	$ (5,366,000)	$ (31,411,000)	$ (16,279,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.12)	$ (0.08)	$ (0.41)	$ (0.24)
Basic and diluted weighted average common shares (in shares)	80,430,061	67,248,384	77,091,624	67,147,584

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (31,612,000)	$ (16,137,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	525,000	1,169,000
Amortization of deferred financing costs and debt discount	961,000	605,000
Joint venture acquisition obligation accretion	362,000	204,000
Provision for doubtful accounts	1,126,000	938,000
Provision for expired enzyme	313,000	0
Change in fair value of warrant liability	(134,000)	(418,000)
Change in fair value of option liability	0	(2,250,000)
Share-based compensation expense	2,566,000	2,723,000
Equity loss from investment in joint venture	0	48,000
Loss on asset disposal	15,000	257,000
Gain on previously held equity interest in joint venture	0	(4,892,000)
Gain on sale of assets	0	(4,392,000)
Loss on debt extinguishment	0	708,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	2,505,000	361,000
Inventories	(1,158,000)	(975,000)
Other current assets	(19,000)	69,000
Other assets	(124,000)	(117,000)
Accounts payable and accrued expenses	(666,000)	(1,080,000)
Deferred revenues, related party	0	(638,000)
Deferred revenues	47,000	(1,245,000)
Long-term deferred rent	(81,000)	(2,000)
Net cash used in operating activities	(25,374,000)	(25,064,000)
Cash flows from investing activities:
Purchases of property and equipment	(792,000)	(536,000)
Expenditures for intellectual property	(255,000)	0
Proceeds from Puregraft divestiture	0	5,000,000
License agreement termination fee	(400,000)	(600,000)
Cash acquired in purchase of the joint venture	0	5,000
Net cash (used in) provided by investing activities	(1,447,000)	3,869,000
Cash flows from financing activities:
Principal payments on long-term obligations	(1,303,000)	(22,292,000)
Proceeds from long-term obligations	0	27,000,000
Debt issuance costs and loan fees	0	(1,744,000)
Joint venture purchase payments	(2,236,000)	(141,000)
Proceeds from exercise of employee stock options and warrants	4,066,000	147,000
Proceeds from sale of common stock	19,075,000	3,001,000
Costs from sale of common stock	(425,000)	(184,000)
Net cash provided by financing activities	19,177,000	5,787,000
Effect of exchange rate changes on cash and cash equivalents	(13,000)	(104,000)
Net decrease in cash and cash equivalents	(7,657,000)	(15,512,000)
Cash and cash equivalents at beginning of period	15,506,000	25,717,000
Cash and cash equivalents at end of period	7,849,000	10,205,000
Cash paid during period for:
Interest	1,972,000	1,592,000
Supplemental schedule of non-cash investing and financing activities:
Fair value of warrants allocated to (from) additional paid-in capital	(296,000)	949,000
Fair value of intangible assets acquired	0	9,394,000
Fair value of tangible assets acquired	0	260,000
Joint venture purchase obligation	0	4,709,000
Fair value of previously held equity interest at acquisition date	$ 0	$ 4,928,000

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2014
Basis of Presentation [Abstract]
Basis of Presentation	1. Basis of Presentation Our accompanying unaudited consolidated condensed financial statements as of September 30, 2014 and for the three and nine months ended September 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at September 30, 2014 has been derived from the audited financial statements at December 31, 2013, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. These financial statements should be read in conjunction with the Consolidated Financial Statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates	9 Months Ended
Use of Estimates	Sep. 30, 2014
Use of Estimates [Abstract]
Use of Estimates	2. Use of Estimates The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, valuing warrants, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventories. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Capital Availability

9 Months Ended

Sep. 30, 2014

Capital Availability [Abstract]

Capital Availability

3.	Capital Availability

We incurred net losses of $9,385,000 and $31,612,000 for the three and nine months ended September 30, 2014 and $5,258,000 and $16,137,000 for the three and nine months ended September 30, 2013, respectively. We have an accumulated deficit of $332,517,000 as of September 30, 2014. Additionally, we have used net cash of $25,374,000 and $25,064,000 to fund our operating activities for the nine months ended September 30, 2014 and 2013, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital and gross profits. On October 8, 2014, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company raised net proceeds of approximately $12,500,000 through the sale of units consisting of Series A 3.6% convertible preferred stock and warrants to purchase common stock.

We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future operations.

We believe our plans to raise additional cash from outside sources coupled with our cost reduction initiatives recently implemented and, if necessary, further cost containment efforts are sufficient to allow us to continue operations for the next twelve months. This includes minimum liquidity requirements of the Loan and Security Agreement, entered into on June 28, 2013 (as amended, the "Loan Agreement"), with Oxford Finance LLC and Silicon Valley Bank (the "Lenders") which requires the Company to make principal and interest payments of $1.0 million per month beginning in April 2015 and to maintain at least three months of cash on hand to avoid an event of default under the Loan Agreement. Our financing plans include pursuing additional cash through strategic corporate partnerships and future sales of equity, as well as our gross profits. While we have an established history of raising capital through these platforms, and we are currently involved in negotiations with multiple parties, there is no guarantee that adequate funds will be available when needed from additional debt or equity financing, development and commercialization partnerships, increased results of operations, or from other sources, or on terms acceptable to us. If our efforts to obtain sufficient additional funds are not successful, we would be required to delay, scale back, or eliminate some or all of our research or product development, manufacturing operations, administrative operations, including our employee base, and clinical or regulatory activities, which could negatively affect our ability to achieve certain corporate goals.

The Company continues to seek additional capital through product revenues, strategic transactions, including extension opportunities under the awarded U.S. Department of Health and Human Service's Biomedical Advanced Research and Development Authority ("BARDA") contract, and from other financing alternatives.

Transactions with Olympus Corporation

9 Months Ended

Sep. 30, 2014

Transactions with Olympus Corporation [Abstract]

Transactions with Olympus Corporation

4.	Transactions with Olympus Corporation

In 2005, we entered into a joint venture and other related agreements (the “Joint Venture Agreements”) with Olympus. The Joint Venture was owned equally by Olympus and us. We had previously accounted for our interests in the Joint Venture using the equity method of accounting, since we could not exert significant influence over the Joint Venture’s operations.

On May 8, 2013, Cytori and Olympus agreed to terminate the Olympus-Cytori Joint Venture (The “Termination Agreement”), and Cytori acquired the remaining 50% equity interest in the Joint Venture from Olympus. The termination of the relationship and purchase of Olympus’ equity shares of the Joint Venture allows Cytori to regain full control of the manufacturing rights for the Celution ® system. The purpose of the acquisition is to gain more flexibility on the manufacturing process and associated costs, enable higher margins, and speed the transition to the critical next-generation systems. In connection with the Termination Agreement, the assets acquired, liabilities assumed, and the Company’s previously held equity interest were recorded at fair value. For valuation purposes Cytori determined the acquisition date (the date on which Cytori effectively gained full control of the equity interest previously held by Olympus) to be May 27, 2013. The remeasurement of the previously held equity interest at the acquisition date resulted in a net gain of $4,892,000 that was recorded in the accompanying Consolidated Condensed Statements of Operations.

As consideration for the Termination Agreement, Cytori can choose from alternative payment options as defined in the Termination Agreement. The payment options call for a minimum of $4,500,000 up to a maximum of $16,000,000 to be paid by Cytori to Olympus in installments over periods ranging from one year to six years depending on the option selected by the Company. Installment payments will be calculated quarterly based on 5% of Cytori’s gross sales receipts for all products sold. If Cytori received an aggregate $35,000,000 in cash through strategic or financing arrangements during the first year of the Termination Agreement, Cytori would have paid $4,500,000 upon request of Olympus as full and complete consideration under the Agreement.

The fair value of the Joint Venture, including the identified intangible assets acquired, consideration transferred, and Cytori’s previously held equity interest, was estimated from a market participant perspective, using valuation techniques based on the income approach for measuring fair value. Specifically, an excess earnings methodology was employed using primarily Level 3 fair value inputs. The intangible assets acquired consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution ® technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. Inputs used in the valuation included various market participant assumptions in order to project potential future cash flows, discounted at a rate commensurate with the risk involved.

	Useful Life (in years)		Estimated Fair Value
Intangible assets:
Developed technology		7	$	9,394,000

The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of acquisition (in thousands):

	Estimated Fair Value
Current assets	$	236
Property and equipment		260
Intangible assets		9,394

Total assets acquired		9,890

Accrued and other current liabilities		(33	)

Total fair value of the Joint Venture	$	9,857

Acquisition-related transaction costs are not included as components of consideration transferred but have been accounted for as expenses in the period in which the costs are incurred.

Revenues and earnings from the Joint Venture were limited to royalties from sales of certain Cytori products, therefore, subsequent to the date of acquisition there was no revenue or earnings from the Joint Venture included in our consolidated results. Had the acquisition occurred on January 1, 2013, consolidated revenue would not have been affected, but our consolidated net loss would have been reduced by $48,000, the amount of our year-to-date equity loss from investment in Joint Venture.

The Company calculated the fair value of the purchase consideration on the acquisition date to be $4,928,000. This was determined using a weighted probability assessment of the payment options available to Cytori. Present value risk-adjusted discount rates applied to the purchase consideration ranged from 9.75% to 12.75%. The fair value calculation of the purchase consideration resulted in a discount of $1,072,000, which will be amortized to interest expense over a weighted average expected term of 1.8 years. On a quarterly basis, the Company will reassess the probabilities of the various payment options and expected term. Changes in the expected term and the remaining discount amount as a result of the reassessment will be recognized prospectively as an adjustment to interest expense. Upon final settlement of the purchase obligation, any difference between the amount paid and the carrying amount of the purchase obligation will be recorded as a gain or loss on extinguishment of the liability. As a result of this reassessment as of March 31, 2014 the Company believed it would settle the obligation for a total of $4.5 million (less any installment payments already made), which would have resulted in a gain of $0.6 million upon settlement.

As of May 8, 2014, the Company’s obligation to Olympus had not been settled, and accordingly, the obligation increased by $1.5 million under an alternative payment option. This option calls for $6.0 million in total payments to be made by May 8, 2015. Since we have made payments totaling $2.7 million through September 30, 2014 our remaining payment obligation under this option is now $3.3 million.

As a result of our quarterly reassessment, we have recorded additional interest expense of $217,000 and $362,000 during the three and nine months ended September 30, 2014, respectively, and have a remaining unrecognized future discount amount of approximately $506,000 as of September 30, 2014.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Partnership Agreement with Lorem Vascular

9 Months Ended

Sep. 30, 2014

Partnership Agreement with Lorem Vascular [Abstract]

Partnership Agreement with Lorem Vascular

5.	Partnership Agreement with Lorem Vascular

On October 29, 2013, we entered into a partnership with Lorem Vascular Pty. Ltd (“Lorem Vascular”), to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets, in China, Hong Kong, Malaysia, Singapore and Australia (the “License/Supply Agreement”), and a Common Stock Purchase Agreement. On January 30, 2014 we entered into the Amended and Restated License/Supply Agreement with Lorem Vascular (the “Restated Agreement”) which restated the License/Supply Agreement in its entirety and expanded the licensed field to all uses excepting alopecia (hair loss). Under the Restated Agreement, Lorem Vascular committed to pay up to $500 million in license fees in the form of revenue milestones. In addition, Lorem is required to pay us 30% of their gross profits in China, Hong Kong and Malaysia for the term of the agreement. In addition, Lorem Vascular has agreed to purchase the Cytori Celution® System and consumables under the Restated Agreement. Pursuant to the related Common Stock Purchase Agreement, Cytori sold Lorem Vascular 8 million shares of Cytori common stock at $3.00 per share for a total of $24 million. The Equity purchased was closed in two installments, the first half in November 2013, and the second half in January 2014.

In addition, Lorem Vascular had initially committed to purchase approximately $7 million in Celution® devices and consumables, with an approximately $2 million order already completed in 2013, and an approximately $5 million order to be placed following regulatory approval in China. Lorem and Cytori have implemented a regulatory plan for China and anticipate approval in 2014.

Long-term Debt

9 Months Ended

Sep. 30, 2014

Long-term Debt [Abstract]

Long-term Debt

6.	Long-term Debt

On June 28, 2013 we entered into the Loan Agreement with the Lenders, pursuant to which the Lenders funded an aggregate principal amount of $27.0 million (Term Loans), subject to the terms and conditions set forth in the loan agreement. The Term Loans accrue interest at a fixed rate of 9.75% per annum. Pursuant to the Loan Agreement, we are required to make interest only payments through July 1, 2014 and thereafter we are required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loans through July 1, 2017, the maturity date. All unpaid principal and interest with respect to the Term Loans is due and payable in full on July 1, 2017. At maturity of the Term Loans, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment fee in an aggregate amount equal to $1,620,000. In connection with the Term Loans, on June 28, 2013, we issued to the Lenders warrants to purchase up to an aggregate of 596,553 shares of our common stock at an exercise price of $2.26 per share. These warrants are immediately exercisable and will expire on June 28, 2020.

In connection with the funding of the Loan Agreement, we prepaid all outstanding amounts under the prior loan agreement, at which time the Company’s obligations under the prior loan agreement immediately terminated. The Company paid to the prior agent and the prior lenders approximately $18,866,000, consisting of the then outstanding principal balance due of approximately $17,325,000, accrued but unpaid interest of approximately $119,000, a final payment fee (net of fees waived or refunded by the Lenders under the new loan agreement) of approximately $1,078,000, a prepayment fee (net of fees waived or refunded by the Lenders under the new loan agreement) of approximately $312,000 and other customary lender fees and expenses.

The net proceeds of the Term Loan, after payment of lender fees and expenses and prepaying all the outstanding amounts relating to the prior loan agreement, were approximately $7.8 million.

For the continuing Lenders, we accounted for this amendment as a debt modification. Accordingly, related fees of $1,942,000 were recorded as debt discount, and along with the unamortized debt discount will be amortized as an adjustment of interest expense using the effective interest method. For one existing lender that did not participate in the Term Loan, the payoff of their loan was accounted for as debt extinguishment. Accordingly, a loss on debt extinguishment of $708,000 was recorded, which includes that lender’s portion of unamortized fees and discounts along with prepayment and final payment fees.

We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values. The fair value of the warrants issued to the Lenders was calculated utilizing the Black-Scholes option pricing model. We are amortizing the resulting additional discount of $949,000 to interest expense over the term of the loan using the effective interest method. The overall effective interest rate for the Term Loan is 13.92%. The Term Loan is collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets.

On September 19, 2014, we entered into a Letter Agreement with the Lenders waiving financial covenant compliance pursuant to the Loan Agreement through October 31, 2014. The Loan Agreement requires the Company to maintain certain minimum cash balances at all times during the term of the Loan Agreement. In exchange for the above waiver, the Company agreed to re-price all 596,553 outstanding warrants issued by the Company to Oxford Finance LLC and Silicon Valley Bank pursuant to the Loan Agreement, with an exercise price per share equal to the lower of (i) the closing price per share of the Company's common stock on September 30, 2014, or (ii) the average closing price per share of the Company's common stock for October 1, 2 and 3, 2014. Following the authoritative accounting guidance, warrants with variable exercise price features are accounted for as liabilities, with changes in the fair value included in operating expenses. The Company estimated the fair value of the warrants immediately before and after modification using an option pricing model to reclassify its fair value from additional paid-in capital to warrant liability and re-measured the warrant liability at September 30, 2014 with the change in fair value of $134,000 accounted for as operating expenses.

The following key assumptions were used by the Company to estimate the fair value of the warrant liability. Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that corresponded to the expected term of the warrants. We believe this method produced an estimate that was representative of our expectations of future volatility over the expected term of these warrants. The expected life was based on the remaining contractual term of the warrants. The risk-free interest rate was the interest rate for treasury constant maturity instruments published by the Federal Reserve Board that was closest to the expected term of the warrants.

On September 29, 2014 we entered into a 2^nd Amendment to the Loan Agreement with the Lenders in which we were provided a conditional waiver of principal payments subject to meeting certain capital raise requirements, which we achieved in October. The waiver of principal payments continues through April 1, 2015 and we are then required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loans through the maturity date.

Revenue Recognition

9 Months Ended

Sep. 30, 2014

Revenue Recognition [Abstract]

Revenue Recognition

7.	Revenue Recognition

Product Sales

We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. For customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction, we defer revenues until collectability is reasonably assured.

For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. Revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books.

For sales that include multiple deliverables, such as sales of our StemSource® Cell Bank (cell bank), we account for products or services (deliverables) separately rather than as a combined unit. Stem cell banks typically consist of a complex array of equipment, proprietary knowledge, license rights, and services, including one or more StemSource® devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting, installation, and training services. Web hosting, technical support and maintenance services are generally provided for a period of up to one year subsequent to the date of sale. FASB authoritative guidance requires an evaluation of these deliverables to determine the appropriate “units of accounting” for purposes of revenue recognition. Each cell bank is customized to provide the best solution for the customer. Depending on customers’ needs, all or a combination of the following units of accounting will apply to cell bank transactions:

initial consulting services;

license rights and standard operating procedures;

equipment and supplies;

installation services;

training services;

database hosting services;

technical support services; and

maintenance services.

FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence (“VSOE”); (b) third-party evidence (“TPE”); or (c) management estimates. This guidance requires arrangement consideration to be allocated at the inception of the arrangement to all deliverables using the relative selling price method. For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available. In the absence of VSOE, we use competitors’ products or services considered largely interchangeable with our own or management’s best estimate. Revenue allocated to each unit of accounting is calculated and recognized based on the relative selling price of each deliverable. Future services such as web hosting and ongoing maintenance are deferred and recognized into income as the services are provided, generally over one year following the installation of the equipment.

Concentration of Significant Customers

Five distributors comprised 62% of our revenue recognized for the nine months ended September 30, 2014. One direct customer and two distributors accounted for 84% of total outstanding accounts receivable as of September 30, 2014.

Three direct customers comprised 39% of our revenue recognized for the nine months ended September 30, 2013. Three direct customers accounted for 54% of total outstanding accounts receivable as of September 30, 2013.

Product revenues, classified by geographic location, are as follows:

	Nine months ended

	September 30, 2014					September 30, 2013
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	614,000		25	%	$	822,000		19	%
Japan		1,323,000		53	%		1,892,000		43	%
Europe		427,000		17	%		865,000		19	%
Other countries		120,000		5	%		837,000		19	%
Total product revenues	$	2,484,000		100	%	$	4,416,000		100	%

Research and Development

We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the BARDA. Revenue earned under development agreements with commercial enterprises is classified as development revenues. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.

In the third quarter of 2012, we were awarded a contract to develop a new countermeasure for thermal burns valued at up to $106 million with BARDA. The initial base period includes $4.7 million over two years and covers preclinical research and continued development of Cytori's Celution® system to improve cell processing. The additional contract options, if fully executed, cover clinical development through FDA approval under a device-based PMA regulatory pathway. In August 2014, BARDA exercised Option 1 of the contract for Cytori to perform research, development, regulatory, clinical and other tasks required for initiation of a pilot clinical trial of the Celution System in thermal burn injury for a total cost-plus fixed fee of up to $12.1 million, amendments to the Statement of Work, and reorganization of the contract options. This is a cost reimbursement contract and related government contract revenue was recorded at the gross amount of reimbursement starting in the fourth quarter of 2012.

We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006. We recorded upfront fees totaling $28,311,000 as deferred revenues, related party. In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution® System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution® System platform. The license and development services were not separable and as a result the recognition of this deferred amount as revenue required achievement of service related milestones, under a proportional performance methodology. Revenue was recognized as the above mentioned R&D milestones were completed. Of the amounts received and deferred, we recognized the last remaining development revenue of $638,000 during the three months ended March 31, 2013 as a result of the United States Court of Appeals upholding the FDA’s previous determination that our cell processing devices were not substantially equivalent to the cited predicate devices. The recognition of revenue associated with this event reflects the completion of our efforts expended to use commercially reasonable efforts to obtain device regulatory approvals in the United States as it pertains to the 510(k) pathway. As of September 30, 2014, there are no deferred amounts under this contract.

Refer to note 14 for discussion about our arrangement with Senko.

Inventories

9 Months Ended

Sep. 30, 2014

Inventories [Abstract]

Inventories

8.	Inventories

Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.

Inventories consisted of the following:

	September 30,		December 31,
	2014		2013

Raw materials	$	1,506,000	$	1,315,000
Work in process		917,000		232,000
Finished goods		2,597,000		2,147,000
	$	5,020,000	$	3,694,000

Equity Incentive Plan

9 Months Ended

Sep. 30, 2014

Equity Incentive Plan [Abstract]

Share-Based Compensation

9.	Equity Incentive Plan

During the third quarter of 2014, we adopted the 2014 Equity Incentive Plan (the "2014 Plan"), which provides our employees, directors and consultants the opportunity to purchase our common stock in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards other stock-based awards, and deferred compensation awards. The 2014 Plan initially provides for issuance of 3,975,000 shares of our common stock. As of September 30, 2014, there are 3,717,500 securities remaining and available for future issuances under the 2014 Plan, which is exclusive of securities to be issued upon an exercise of outstanding options, warrants, and rights.

Loss per Share

9 Months Ended

Sep. 30, 2014

Loss per Share [Abstract]

Loss per Share

10.	Loss per Share

Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented.

We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the three and nine months ended September 30, 2014 and 2013, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 18,748,777 for the three and nine month periods ended September 30, 2014 and 17,212,805 for the three and nine month periods ended September 30, 2013.

Accumulated Other Comprehensive Loss

9 Months Ended

Sep. 30, 2014

Accumulated Other Comprehensive Loss [Abstract]

Accumulated Other Comprehensive Loss

11.	Accumulated Other Comprehensive Loss

During the first quarter of 2013, we determined that the functional currency of our Japanese subsidiary changed from the US Dollar to the Japanese Yen due to significant changes in economic facts and circumstances of our Japan subsidiary. As a result of this change, a portion of the foreign exchange gain or loss will be classified as foreign currency translation adjustments within other comprehensive income or loss. Our comprehensive loss includes net loss and foreign currency translation adjustments. See the unaudited Consolidated Condensed Statements of Operations and Comprehensive Loss for the effect of foreign currency translation adjustments.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies [Abstract]

Commitments and Contingencies

12.	Commitments and Contingencies

We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study in progress. As of September 30, 2014, we have clinical research study obligations of $6,358,000 ($4,785,000 of which are expected to be complete within a year). Should the timing of the clinical trials change, the timing of the payment of these obligations would also change.

We have entered into several lease agreements for our headquarters office location as well as international office locations. As of September 30, 2014, we have remaining lease obligations of $6,919,000 ($2,197,000 of which are expected to be completed within a year).

We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations.

Refer to note 4 for a discussion of our commitments and contingencies related to our transactions with Olympus.

Refer to note 14 for a discussion of our commitments and contingencies related to our arrangements with Senko.

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC

9 Months Ended

Sep. 30, 2014

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC [Abstract]

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC

13.	Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC

On July 30, 2013, we entered into a Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC (“Bimini”), pursuant to which we sold to Bimini substantially all of the assets (other than certain retained rights and licenses) of our Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring. The aggregate value of the consideration paid by Bimini at the execution of the agreement was $5.0 million.

In connection with the sale, Bimini granted to the Company an exclusive, perpetual, royalty bearing license to market and sell the Puregraft products for use in combination with adipose derived regenerative cells, and non-exclusive rights for use in connection with the Company’s licensed cell and tissue banks. The Company will supply Puregraft products to Bimini on an interim basis until the Company transfers the manufacturing of the Puregraft products to Bimini. After the transfer, Bimini will supply the Puregraft products to the Company.

Pursuant to the sale agreement, the Company has also granted to Bimini the global, exclusive, perpetual, irrevocable royalty bearing license to purchase from Cytori, use and sell the Celution® System products for Alopecia (hair loss). Cytori will supply Celution devices and consumable sets to Bimini, and Bimini will be responsible for all costs associated with commercial development in the Alopecia market.

The agreement includes certain obligations to be performed by the Company on the behalf of Bimini, which includes transferring the manufacturing of Puregraft products to an agreed upon third party on or before December 31, 2014 and training. The Company recorded a gain on the Puregraft divestiture of $4.5 million in 2013, and has a remaining obligation of approximately $158,000 in future transfer and training obligations, as of September 30, 2014. Bimini is obligated to make certain additional milestone payments to the Company (in an aggregate amount of up to $10.0 million), contingent upon the achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products.

Thin Film Japan Distribution Agreement

9 Months Ended

Sep. 30, 2014

Thin Film Japan Distribution Agreement [Abstract]

Thin Film Japan Distribution Agreement

14.	Thin Film Japan Distribution Agreement

In 2004, the Company entered into a Distribution Agreement with Senko. Under this agreement, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan and are responsible for the completion of the initial regulatory application to the Ministry of Health, Labor and Welfare (MHLW) and commercialization of the Thin Film product line in Japan. The Distribution Agreement with Senko was to commence upon “commercialization.” Essentially, commercialization occurs when one or more Thin Film product registrations are completed with the MHLW. At the inception of this arrangement, we received a $1,500,000 license fee which was recorded as deferred revenues in 2004. Half of the license fee was refundable if the parties agree commercialization is not achievable and a proportional amount was refundable if we terminate the arrangement, other than for material breach by Senko, before three years post-commercialization. We have also received $1,250,000 in milestone payments from Senko.

In February 2013, we entered into a mutual termination and release agreement with Senko, whereby the Distribution Agreement and all Senko rights, licenses and privileges granted under the Distribution Agreement terminated and reverted to the Company. As a result of this Termination Agreement, we were obligated to pay Senko $1,200,000 in six quarterly installment payments of $200,000 each through May 2014 (all of which has been paid). At the time of the Termination Agreement, we had a balance of $2,379,000 in deferred revenues on our balance sheet relating to the payments received from Senko in the past pursuant to the Distribution Agreement. At the time of the Termination Agreement we accrued $1,200,000 of the termination fee, and recognized the remaining $1,179,000 in development revenues which reflects the Company’s efforts towards commercialization under the agreement. As of September 30, 2014, we have no remaining termination fee obligation.

Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Fair Value Measurements

15.	Fair Value Measurements

Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:

· Level 1: Quoted prices in active markets for identical assets or liabilities.

· Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

· Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of		Basis of Fair Value Measurements
	September 30, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,644,000	$	3,644,000	$	—	$	—

Liabilities:
Warrant liability	$	287,000	$	—	$	—	$	287,000

	Balance as of		Basis of Fair Value Measurements
	December 31, 2013		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	4,644,000	$	4,644,000	$	—	$	—

We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.

Refer to note 6 for discussion about determining the fair value of our warrant liability.

Common stock purchase warrants issued in connection with our Letter Agreement with the Lenders do not trade in an active securities market, and as such, we estimated the fair value of these warrants using the option pricing model (see note 6). Some of the significant inputs are observable in active markets, such as common stock market price, volatility, and risk free rate. Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

The following table summarizes the change in our Level 3 warrant liability value:

	Three months ended			Nine months ended
Warrant liability	September 30, 2014			September 30, 2014

Beginning balance	$	—		$	—
Fair value of warrants allocated from additional paid in capital		421,000			421,000
Decrease in fair value recognized in operating expenses		(134,000	)		(134,000	)
Ending balance	$	287,000		$	287,000

Fair Value

9 Months Ended

Sep. 30, 2014

Fair Value [Abstract]

Fair Value

16.	Fair Value

Financial Instruments

We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at September 30, 2014 and December 31, 2013, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.

We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.

At September 30, 2014 and December 31, 2013, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:

	September 30, 2014				December 31, 2013

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	25,328,000	$	25,775,000	$	26,207,000	$	26,241,000

Carrying value is net of debt discount of $1,631,000 and $2,379,000 as of September 30, 2014 and December 31, 2013, respectively.

The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

9 Months Ended

Sep. 30, 2014

Stockholders' Equity [Abstract]

Stockholders' Equity

17.	Stockholders’ Equity

Common Stock

In December 2012, we entered into an underwriting agreement with Lazard Capital Markets, LLC (underwriter), relating to the issuance and sale of 7,020,000 shares of our common stock. The price to the public in this offering was $2.85 per share and the underwriter purchased the shares from us at a price of $2.69 per share. The transaction was completed on December 19, 2012 raising approximately $20,007,000 in gross proceeds before deducting underwriting discounts and commissions and other offering expenses payable by us. Under the terms of the underwriting agreement, we granted the underwriter an option, exercisable for 30 days, to purchase up to an additional 1,053,000 shares.

In January 2013, the underwriter exercised this option and as a result we sold an additional 1,053,000 shares raising approximately $3,001,000 in gross proceeds before deducting underwriting discounts and commissions and other offering expenses payable by us.

In October 2013, we entered into a Common Stock Purchase Agreement with Lorem Vascular for the purchase of 8,000,000 shares at $3.00 per share. The transaction occurred in two separate closings of 4,000,000 shares each. The first closing occurred in November 2013, and the second closing occurred in January 2014. As of December 31, 2013, we received $15,000,000 of the gross proceeds, $12,000,000 for the first closing and $3,000,000 towards the second closing. The balance of $9,000,000 in gross proceeds required to complete the second closing was received in January 2014.

In May 2014, we and 47 holders of warrants to purchase a total of 3,156,238 shares of the Company’s common stock, $0.001 par value per share, issued in a private offering in May 2009, agreed to extend the expiration date of the warrants from May 14, 2014 to May 14, 2015 and increase the exercise price of the warrants from $2.62 per share to $3.50 per share pursuant to an Amendment to Warrant to Purchase Common Stock. One holder of warrants did not agree to the Amendment, and their warrants, covering 38,500 shares of Common Stock, expired unexercised on May 14, 2014 in accordance with the original terms.

In May 2014, we entered into subscription agreements with certain institutional investors pursuant to which we sold a total of 4,048,584 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a purchase price of $2.47 per unit, in a registered direct offering. Each warrant will have an exercise price of $3.00 per share, will be exercisable immediately after issuance and will expire five years from the date of issuance. The transaction was completed on June 4, 2014 raising approximately $10,000,000 in gross proceeds before deducting any offering expenses or fees payable by us. Under the terms of our Placement Agent Agreement, we granted WBB Securities, LLC warrants to purchase 202,429 shares of common stock. The placement agent warrants will have the same terms as the warrants issued to the purchasers in the offering, except that such warrants will have an exercise price of $3.09.

In September 2014, the Company and 13 holders of warrants dated June 4, 2014 to purchase a total of 4,032,389 shares of the Company's common stock, $0.001 par value per share, agreed to amend the warrants in order to reduce the exercise price from $3.00 per share to $1.00 per share and change the expiration date from June 4, 2019 to September 10, 2014 pursuant to an amendment to warrant to purchase common stock. The Company received proceeds of approximately $4,000,000 from exercise of the Warrants. In addition, pursuant to the terms of the amendment, upon each holder's exercise of all shares for cash prior to the amended expiration date, the Company issued a new warrant for the same number of shares to holder. The additional warrants have an exercise price of $2.00 per share, and are exercisable on the date that is six months and one day from the date of issuance and expire five years from the date of issuance.

Related Party Transactions

During the nine months ended September 30, 2013, we incurred approximately $46,000, in royalty costs in connection with our sales of our Celution® 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture. There were no comparable royalty costs during the nine months ended September 30, 2014.

Additionally, refer to note 4 for a discussion of related party transactions with Olympus.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

Subsequent Events

18.	Subsequent Events

On October 8, 2014, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company sold a total of 13,500 units for a purchase price of $1,000 per unit, with each unit consisting of one share of the Company's Series A 3.6% convertible preferred stock, which are convertible into shares of the Company's common stock, par value of $0.001 per share, with a conversion price of $0.52, and warrants to purchase up to a number of shares of common stock equal to 100% of the conversion shares under the shares of preferred stock, in a registered direct offering. Each warrant has an exercise price of $0.5771 per share, is exercisable six months after the date of issuance and expires five years from the date on which it is initially exercisable. The preferred stock and the warrants were immediately separable and were issued separately. As of October 31, 2014, we have converted 4,615 units into 8,875,000 shares of common stock.

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2014
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation Our accompanying unaudited consolidated condensed financial statements as of September 30, 2014 and for the three and nine months ended September 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at September 30, 2014 has been derived from the audited financial statements at December 31, 2013, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. These financial statements should be read in conjunction with the Consolidated Financial Statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates (Policies)	9 Months Ended
Use of Estimates (Policies)	Sep. 30, 2014
Use of Estimates [Abstract]
Use of Estimates	Use of Estimates The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, valuing warrants, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventories. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Revenue Recognition (Policies)

9 Months Ended

Sep. 30, 2014

Revenue Recognition [Abstract]

Revenue Recognition

7.	Revenue Recognition

Product Sales

initial consulting services;

license rights and standard operating procedures;

equipment and supplies;

installation services;

training services;

database hosting services;

technical support services; and

maintenance services.

Concentration of Significant Customers

Product revenues, classified by geographic location, are as follows:

	Nine months ended

	September 30, 2014					September 30, 2013
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	614,000		25	%	$	822,000		19	%
Japan		1,323,000		53	%		1,892,000		43	%
Europe		427,000		17	%		865,000		19	%
Other countries		120,000		5	%		837,000		19	%
Total product revenues	$	2,484,000		100	%	$	4,416,000		100	%

Research and Development

Refer to note 14 for discussion about our arrangement with Senko.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Transactions with Olympus Corporation (Tables)

9 Months Ended

Sep. 30, 2014

Transactions with Olympus Corporation [Abstract]

Schedule of Acquired Intangible Assets

Inputs used in the valuation included various market participant assumptions in order to project potential future cash flows, discounted at a rate commensurate with the risk involved.

	Useful Life (in years)		Estimated Fair Value
Intangible assets:
Developed technology		7	$	9,394,000

Schedule of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of acquisition (in thousands):

	Estimated Fair Value
Current assets	$	236
Property and equipment		260
Intangible assets		9,394

Total assets acquired		9,890

Accrued and other current liabilities		(33	)

Total fair value of the Joint Venture	$	9,857

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2014

Revenue Recognition [Abstract]

Product Revenues by Geographic Location

Product revenues, classified by geographic location, are as follows:

	Nine months ended

	September 30, 2014					September 30, 2013
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	614,000		25	%	$	822,000		19	%
Japan		1,323,000		53	%		1,892,000		43	%
Europe		427,000		17	%		865,000		19	%
Other countries		120,000		5	%		837,000		19	%
Total product revenues	$	2,484,000		100	%	$	4,416,000		100	%

Inventories (Tables)

9 Months Ended

Sep. 30, 2014

Inventories [Abstract]

Inventory

Inventories consisted of the following:

	September 30,		December 31,
	2014		2013

Raw materials	$	1,506,000	$	1,315,000
Work in process		917,000		232,000
Finished goods		2,597,000		2,147,000
	$	5,020,000	$	3,694,000

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Assets and Liabilities Measured at Fair Value

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of		Basis of Fair Value Measurements
	September 30, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,644,000	$	3,644,000	$	—	$	—

Liabilities:
Warrant liability	$	287,000	$	—	$	—	$	287,000

	Balance as of		Basis of Fair Value Measurements
	December 31, 2013		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	4,644,000	$	4,644,000	$	—	$	—

Change in Level 3 Warrant Liability Value

The following table summarizes the change in our Level 3 warrant liability value:

	Three months ended			Nine months ended
Warrant liability	September 30, 2014			September 30, 2014

Beginning balance	$	—		$	—
Fair value of warrants allocated from additional paid in capital		421,000			421,000
Decrease in fair value recognized in operating expenses		(134,000	)		(134,000	)
Ending balance	$	287,000		$	287,000

Fair Value (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value [Abstract]

Fair Value and Carrying Value of Long-term Debt

At September 30, 2014 and December 31, 2013, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:

	September 30, 2014				December 31, 2013

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	25,328,000	$	25,775,000	$	26,207,000	$	26,241,000

Capital Availability (Details) - USD ($)	3 Months Ended		9 Months Ended
Capital Availability (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Capital Availability [Abstract]
Net loss	$ (9,385,000)	$ (5,258,000)	$ (31,612,000)	$ (16,137,000)
Accumulated deficit	(332,517,000)		(332,517,000)		$ (300,905,000)
Net cash used			25,374,000	$ 25,064,000
Proceeds from sale of Series A 3.6% convertible preferred stock and warrants to purchase common stock	$ 12,500,000
Periodic payments beginning August 2014			$ 1,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Transactions with Olympus Corporation (Details) - USD ($)			3 Months Ended			9 Months Ended
	May 08, 2014	May 27, 2013	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	May 31, 2013	May 08, 2013
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Remeasurement gain			$ 0		$ 0	$ 0	$ 4,892,000
Inputs used in valuation of acquired intangible assets [Abstract]
Additional interest expense			217,000			362,000
Remaining Unrecognized Future Discount			506,000			506,000
Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]
Option liability								$ 0
Acquired Olympus Ownership [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Equity interest acquired (in hundredths)									50.00%
Acquisition agreement date		May 27, 2013
Payment obligation under termination agreement			2,700,000			2,700,000
Installment payment amount description		Installment payments will be calculated quarterly based on 5% of Cytori’s gross sales receipts for all products sold. If Cytori receives an aggregate $35,000,000 in cash through strategic or financing arrangements during the first year of the Termination Agreement, Cytori will pay $4,500,000 upon request of Olympus as full and complete consideration under the Agreement.
Gross sales receipts (in hundredths)		5.00%
Limit for cash through strategic or financing arrangements		$ 35,000,000
Required payment for acquisition		4,500,000
Inputs used in valuation of acquired intangible assets [Abstract]
Estimated fair value									$ 9,394,000
Fair value of purchase consideration		4,928,000
Unamortized discount resulting from fair value calculation of purchase obligations		$ 1,072,000
Weighted average expected term for amortization of purchase obligation		1 year 9 months 18 days
Year-to-date equity loss from investment in Joint Venture		$ 48,000
Gain on remeasurement of purchase obligation				$ 600,000
Increase in settlement obligation	$ 1,500,000
Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]
Current assets									236,000
Property and equipment									260,000
Intangible assets									9,394,000
Total assets acquired									9,890,000
Accrued and other current liabilities									(33,000)
Total fair value of the Joint Venture									$ 9,857,000
Acquired Olympus Ownership [Member] \| Alternative Payment Option One [Member]
Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]
Option liability			3,300,000			$ 3,300,000
Acquired Olympus Ownership [Member] \| Alternative Payment Option Two [Member]
Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]
Option liability	$ 6,000,000
Acquired Olympus Ownership [Member] \| Minimum [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Payment obligation under termination agreement		$ 4,500,000
Payment installment period		1 year
Inputs used in valuation of acquired intangible assets [Abstract]
Present value risk-adjusted discount rates (in hundredths)		9.75%
Acquired Olympus Ownership [Member] \| Maximum [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Payment obligation under termination agreement		$ 16,000,000
Payment installment period		6 years
Inputs used in valuation of acquired intangible assets [Abstract]
Present value risk-adjusted discount rates (in hundredths)		12.75%
Acquired Olympus Ownership [Member] \| Developed Technology [Member]
Inputs used in valuation of acquired intangible assets [Abstract]
Useful life (in years)						7 years
Estimated fair value			9,394,000			$ 9,394,000
Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]
Intangible assets			$ 9,394,000			$ 9,394,000

Partnership Agreement with Lorem Vascular (Details) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2014 USD ($) Installment $ / shares shares
Product Purchase Commitment [Member]
Partnership Agreement [Line Items]
Second purchase commitment	$ 5
Lorem Vascular [Member] \| Equity Purchases [Member]
Partnership Agreement [Line Items]
Shares of unregistered stock purchased (in shares) \| shares	8
Equity purchase price (in dollars per share) \| $ / shares	$ 3.00
Proceeds from sale of shares	$ 24
Number of installments in equity purchases \| Installment	2
Lorem Vascular [Member] \| Product Purchase Commitment [Member]
Partnership Agreement [Line Items]
Total commitment	$ 500
Gross profits percentage (in hundredths)	30.00%
First purchase commitment	$ 7
Order already placed	$ 2

Long-term Debt (Details) - USD ($)		3 Months Ended		9 Months Ended
Long-term Debt (Details) - USD ($)	Jun. 28, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 19, 2014	Sep. 10, 2014	Jun. 30, 2014	Jun. 04, 2014	May 31, 2014
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)		$ 2.00		$ 2.00			$ 1.00	$ 3.50	$ 3.00	$ 2.62
Repayment of long term debt				$ 1,303,000	$ 22,292,000
Net proceeds of the Term Loan, after payment of lender fees and expenses				0	27,000,000
Outstanding warrants issued and re-priced (in shares)	596,553
Change in fair value of warrant liability		$ 134,000	$ 0	134,000	418,000
Loss on debt extinguishment		$ 0	$ 0	$ 0	$ 708,000
Term Loan [Member]
Debt Instrument [Line Items]
Origination date	Jun. 28, 2013
Original loan amount	$ 27,000,000
Interest rate (in hundredths)	9.75%
Maturity date	Jul. 01, 2017
Fees amount associated with loan	$ 1,620,000
Date from which warrants are exercisable	Jun. 28, 2013
Warrants issued to lenders (in shares)	596,553					596,553
Warrant exercise price (in dollars per share)	$ 2.26					$ 2.00
Warrant expiration date	Jun. 28, 2020
Repayment of long term debt	$ 18,866,000
Term Loan remaining balance at date of Amendment	17,325,000
Accrued but unpaid interest	119,000
Final payment fee	1,078,000
Prepayment fee	312,000
Net proceeds of the Term Loan, after payment of lender fees and expenses	7,800,000
Unamortized debt discount	$ 949,000
Effective interest rate (in hundredths)	13.92%
Loss on debt extinguishment	$ 708,000
Term Loan [Member] \| Final Payment [Member]
Debt Instrument [Line Items]
Fees amount associated with loan	$ 1,942,000

Revenue Recognition (Details)	3 Months Ended				9 Months Ended
Revenue Recognition (Details)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2014 USD ($) Distributor Customer	Sep. 30, 2013 USD ($) Customer
Revenue Recognition [Abstract]
Period of services provided subsequent to date of sale					1 year
Revenues from External Customers and Long-Lived Assets [Line Items]
Product revenues	$ 518,000	$ 1,616,000			$ 2,484,000	$ 4,416,000
Concentration risk percentage (in hundredths)					100.00%	100.00%
Research and Development Arrangements [Line Items]
Deferred revenue, related party, revenue recognized			$ 638,000
Costs associated with the development device	3,140,000	$ 4,123,000			$ 12,106,000	$ 11,992,000
Maximum total cost-plus fixed fee	$ 12,100,000				$ 12,100,000
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of distributors \| Distributor					5
Number of customers \| Customer						3
Concentration risk percentage (in hundredths)					62.00%	39.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of distributors \| Distributor					2
Number of customers \| Customer					1	3
Concentration risk percentage (in hundredths)					84.00%	54.00%
Olympus and Olympus-Cytori [Member]
Research and Development Arrangements [Line Items]
Deferred revenues, related party				$ 28,311,000
BARDA Contract [Member]
Research and Development Arrangements [Line Items]
Costs associated with the development device				106,000,000
Research and development arrangement with federal government, customer funding to offset costs incurred				$ 4,700,000
Research and development arrangement, initial base period				2 years
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Product revenues					$ 614,000	$ 822,000
Concentration risk percentage (in hundredths)					25.00%	19.00%
Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Product revenues					$ 1,323,000	$ 1,892,000
Concentration risk percentage (in hundredths)					53.00%	43.00%
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Product revenues					$ 427,000	$ 865,000
Concentration risk percentage (in hundredths)					17.00%	19.00%
Other countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Product revenues					$ 120,000	$ 837,000
Concentration risk percentage (in hundredths)					5.00%	19.00%

Inventories (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 1,506,000	$ 1,315,000
Work in process	917,000	232,000
Finished goods	2,597,000	2,147,000
Inventory, net	$ 5,020,000	$ 3,694,000

Equity Incentive Plan (Details)	9 Months Ended
Equity Incentive Plan (Details)	Sep. 30, 2014 shares
Equity Incentive Plan [Abstract]
Common stock shares to be issued	3,975,000
Common stock shares remaining and available fo future issuances	3,717,500

Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
Loss per Share (Details) - shares	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Loss per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	18,748,777	17,212,805	18,597,735	17,212,805

Commitments and Contingencies (Details)	Sep. 30, 2014 USD ($)
Clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation, due in next twelve months	$ 4,785,000
Purchase obligation	6,358,000
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, due in next twelve months	2,197,000
Contractual obligation	$ 6,919,000

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC (Details) - USD ($)	Jul. 30, 2013	Sep. 30, 2014
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC [Abstract]
Aggregate value of consideration paid by Bimini	$ 5,000,000
Gain (Loss) on Sale of Business	$ 4,500,000
Estimated future transfer and training obligations		$ 158,000
Milestone payments, maximum		$ 10,000,000

Thin Film Japan Distribution Agreement (Details)	1 Months Ended	3 Months Ended		9 Months Ended
Thin Film Japan Distribution Agreement (Details)	Feb. 28, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($) Installment	Sep. 30, 2013 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2004 USD ($)
Thin Film Japan Distribution Agreement [Abstract]
License fee recorded as deferred revenue	$ 2,379,000	$ 168,000		$ 168,000			$ 212,000	$ 1,500,000
Period before post commercialization in case of termination for proportional refund				3 years
Milestone payments received				$ 1,250,000
Number of installment payments \| Installment				6
Periodic payment under termination agreement				$ 200,000
Deferred revenues	2,379,000	168,000		168,000			$ 212,000	$ 1,500,000
Termination fee obligation	1,200,000					$ 0
Development revenue	$ 1,179,000	$ 0	$ 0	$ 0	$ 1,179,000

Fair Value Measurements (Details) - USD ($)	3 Months Ended	9 Months Ended
Fair Value Measurements (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Measurements, Recurring [Member]
Assets [Abstract]
Cash equivalents	$ 3,644,000	$ 3,644,000	$ 4,644,000
Liabilities:
Warrant liability	287,000	287,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Cash equivalents	3,644,000	3,644,000	4,644,000
Liabilities:
Warrant liability	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Cash equivalents	0	0	0
Liabilities:
Warrant liability	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Cash equivalents	0	0	$ 0
Liabilities:
Warrant liability	287,000	287,000
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0	0
Fair value of warrants allocated from additional paid in capital	421,000	421,000
Decrease in fair value recognized in operating expenses	(134,000)	(134,000)
Ending balance	$ 287,000	$ 287,000

Fair Value (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	$ 25,328,000	$ 26,207,000
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	25,775,000	26,241,000
Debt discount	$ 1,631,000	$ 2,379,000

Stockholders' Equity (Details)	1 Months Ended			9 Months Ended		12 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2014 USD ($) WarrantHolder $ / shares shares	May 31, 2014 USD ($) WarrantHolder $ / shares shares	Jan. 31, 2013 USD ($) shares	Sep. 30, 2014 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)	Dec. 31, 2013 USD ($) Closing $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Sep. 10, 2014 $ / shares	Jun. 30, 2014 $ / shares	Jun. 04, 2014 $ / shares
Common Stock [Abstract]
Proceeds from private placement of stock \| $	$ 4,000,000
Period exercisable from the date of issuance	six months and one day
Number of warrant holders \| WarrantHolder	13	47
Number of shares called by warrants (in shares)	4,032,389	3,156,238		4,032,389
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.00	$ 2.62		$ 2.00				$ 1.00	$ 3.50	$ 3.00
Number of holders who did not agree to Amendment \| WarrantHolder		1
Number of shares called by warrants that expired unexercised (in shares)		38,500
Period in which warrants will expire		5 years
Olympus-Cytori, Inc. Joint Venture [Member]
Related Party Transaction [Line Items]
Royalty costs in connection with sales \| $				$ 0	$ 46,000
Lazard Capital Markets, LLC [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $			$ 3,001,000				$ 20,007,000
Convertible Preferred Stock (in units)			1,053,000				7,020,000
Common stock at a purchase price (in dollars per unit) \| $ / shares							$ 2.85
Sale of stock, price per share (in dollars per share) \| $ / shares							$ 2.69
Purchase period of common stock							30 days
Lorem Vascular [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $						$ 15,000,000
Convertible Preferred Stock (in units)						8,000,000
Sale of stock, price per share (in dollars per share) \| $ / shares						$ 3.00
Number of closings \| Closing						2
Receivables from sale of stock \| $						$ 9,000,000
Lorem Vascular [Member] \| First Closing of Stock sale [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $						$ 12,000,000
Convertible Preferred Stock (in units)						4,000,000
Lorem Vascular [Member] \| Second Closing of Stock sale [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $						$ 3,000,000
Convertible Preferred Stock (in units)						4,000,000
WBB Securities, LLC [Member]
Common Stock [Abstract]
Number of shares called by warrants (in shares)		202,429
Exercise price of warrants (in dollars per share) \| $ / shares		$ 3.09
Institutional Investors [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $		$ 10,000,000
Convertible Preferred Stock (in units)		4,048,584
Sale of stock, price per share (in dollars per share) \| $ / shares		$ 2.47
Exercise price of warrants (in dollars per share) \| $ / shares		$ 3.00
Period in which warrants will expire		5 years
Number of common stock available in each unit of subscription agreement (in shares)		1
Number of warrants available in each unit of subscription agreement (in shares)		1

Subsequent Events (Details) - $ / shares			1 Months Ended
Subsequent Events (Details) - $ / shares	Oct. 31, 2014	Oct. 08, 2014	Sep. 30, 2014	May 31, 2014	Sep. 10, 2014	Jun. 30, 2014	Jun. 04, 2014	Dec. 31, 2013
Subsequent Event [Line Items]
Par value per share (in dollars per share)			$ 0.001	$ 0.001				$ 0.001
Exercise price of warrants (in dollars per share)			$ 2.00	$ 2.62	$ 1.00	$ 3.50	$ 3.00
Period exercisable from the date of issuance			six months and one day
Period in which warrants will expire				5 years
Institutional Investors [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock (in units)				4,048,584
Each unit consist of number of common stock (in shares)				1
Exercise price of warrants (in dollars per share)				$ 3.00
Period in which warrants will expire				5 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of warrants (in dollars per share)		$ 0.5771
Period exercisable from the date of issuance		Six Months
Period in which warrants will expire		5 years
Units Converted (in shares)	4,615
Subsequent Event [Member] \| Institutional Investors [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock (in units)		13,500
Common stock at a purchase price (in dollars per unit)		$ 1,000
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Par value per share (in dollars per share)		$ 0.001
Units Converted (in shares)	8,875,000
Subsequent Event [Member] \| Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Each unit consist of number of common stock (in shares)		1
Convertible preferred stock (in hundredths)		3.60%
Conversion Price (in dollars per share)		$ 0.52
Convertible Preferred Stock, Terms of Conversion		number of shares of common stock equal to 100% of the conversion shares under the shares of preferred stock